Literature DB >> 119641

Urinary bile acids in late pregnancy and in recurrent cholestasis of pregnancy.

P A Thomassen.   

Abstract

The metabolic profiles of urinary bile acids in pregnant women in the last trimester and patients with recurrent intrahepatic cholestasis of pregnancy (RCP) were studied. Following separation according to mode of conjugation, about thirty different bile acids were quantitatively analysed by gas chromatography-mass spectrometry. In all patients the sulphate fraction comprised 50--90% of the total bile acids. In RCP a shift from glycine to taurine conjugation was noted to together with a slight relative increase in sulphation. A ten- to hundred-fold increase in cholic and chenodeoxycholic acids was seen in RCP, the increase being mainly in the sulphate fraction. Tetrahydroxylated bile acids, tentatively regarded as 1- and 6-hydroxylated products of cholic acid, were quantitatively important in patients with RCP. The relative amounts of the secondary bile acids, deoxycholic and lithocholic acids, decreased with increasing cholestasis. Metabolites hydroxylated at C-6 were common, and the excretion of hydroxylated at C-6 were common, and the excretion of hyocholic acid was positively correlated to that of chenodeoxycholic acid. An increase in the excretion of 5 alpha-configurated bile acids in RCP was noted. A positive correlation between the excretion of 3 beta-hydroxy-5-cholenoic acid and 3 beta,12 alpha-dihydroxy-5-cholenoic acid indicates a metabolic relationship between the two compounds. Because of the relatively small amounts of lithocholic and 3 beta-hydroxy-5-cholenoic acids in patients with RCP, these compounds do not seem to be of pathogenetic importance in this type of cholestasis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 119641     DOI: 10.1111/j.1365-2362.1979.tb00907.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  8 in total

Review 1.  Intrahepatic cholestasis of pregnancy.

Authors:  Victoria Geenes; Catherine Williamson
Journal:  World J Gastroenterol       Date:  2009-05-07       Impact factor: 5.742

Review 2.  The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis.

Authors:  Jiezhong Chen; Kong-Nan Zhao; Chen Chen
Journal:  Ann Transl Med       Date:  2014-01

3.  Fifty years with bile acids and steroids in health and disease.

Authors:  Jan Sjövall
Journal:  Lipids       Date:  2004-08       Impact factor: 1.880

4.  Altered bile acid metabolism in primary biliary cirrhosis.

Authors:  R Raedsch; B H Lauterburg; A F Hofmann
Journal:  Dig Dis Sci       Date:  1981-05       Impact factor: 3.199

5.  Postnatal physiologic hypercholemia in both premature and full-term infants.

Authors:  S Barnes; G Berkowitz; B I Hirschowitz; D Wirtschafter; G Cassady
Journal:  J Clin Invest       Date:  1981-09       Impact factor: 14.808

Review 6.  Nuclear receptors as therapeutic targets in cholestatic liver diseases.

Authors:  Gernot Zollner; Michael Trauner
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

Review 7.  Farnesoid X receptor alpha: a molecular link between bile acids and steroid signaling?

Authors:  Marine Baptissart; Aurelie Vega; Emmanuelle Martinot; Silvère Baron; Jean-Marc A Lobaccaro; David H Volle
Journal:  Cell Mol Life Sci       Date:  2013-06-20       Impact factor: 9.261

8.  Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis.

Authors:  R Wang; M Salem; I M Yousef; B Tuchweber; P Lam; S J Childs; C D Helgason; C Ackerley; M J Phillips; V Ling
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.